ImmunityBio
ImmunityBio Inc is an American clinical and commercial-stage immunotherapy enterprise specializing in the research, development, manufacturing, and commercialization of innovative biological therapeutic product candidates (including lymphokine-activated killer cells, monoclonal antibodies, fusion proteins, and cancer vaccines) designed to activate the patient's adaptive and innate immune system to combat complex cancers and infectious diseases. The company operates advanced biotechnology manufacturing and research complexes, prominently featuring FDA-approved immunotherapy products. Its core business operations encompass immunotherapy drug development, biological manufacturing, clinical trial administration, and commercial pharmaceutical distribution. Revenue is derived primarily from commercial product sales of approved immunotherapies and strategic biopharmaceutical collaboration agreements. ImmunityBio holds a leading market position in immunotherapy innovation and cancer vaccine development. The company is headquartered in Culver City, California, United States, and its common stock trades on the Nasdaq Global Select Market under the ticker IBRX.
6 of the funds FundTelligence covers report a position in ImmunityBio.
- Legal name
- ImmunityBio Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 6
Funds holding ImmunityBio
- SEB Läkemedelsfond — SEB · 1.19 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.59 % (full portfolio disclosed, October 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.3 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.03 % (partially disclosed portfolio, June 2026)